Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioreductive mechanisms.

P Workman1

  • 1CRC Department of Medical Oncology, University of Glasgow, Bearsden, UK.

International Journal of Radiation Oncology, Biology, Physics
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Developing effective bioreductive antitumor agents requires understanding tumor hypoxia and the enzymes that activate them. This review focuses on quinone, nitro, and N-oxide compounds for cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Oncogene·2020
Same author

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Blood cancer journal·2017
Same author

A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset.

Psychological medicine·2016
Same author

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Oncogene·2013
Same author

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

British journal of cancer·2013
Same author

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

Clinical pharmacology and therapeutics·2013
Same journal

Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial.

International journal of radiation oncology, biology, physics·2026
Same journal

Proton beam therapy in nonmetastatic rhabdomyosarcoma: Outcome, prognostic factors and the effect of timing of radiation therapy.

International journal of radiation oncology, biology, physics·2026
Same journal

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026
Same journal

Gastrointestinal Motility-Induced Interplay in Pancreas Proton Therapy: Motion Simulation and Dosimetric Impact.

International journal of radiation oncology, biology, physics·2026
Same journal

Intra-fractional Voxel-wise Anatomical Motion Tracking Guided by Multimodal Respiratory Surrogates in Radiotherapy: Framework Development and Multi-Center Validation.

International journal of radiation oncology, biology, physics·2026
Same journal

A Gaussian-based planning approach for robust dose-escalated stereotactic body proton therapy.

International journal of radiation oncology, biology, physics·2026
See all related articles

Area of Science:

  • Biomedical science
  • Medicinal chemistry
  • Cancer research

Background:

  • Bioreductive agents offer targeted cancer therapy.
  • Rational drug design necessitates understanding drug activation and tumor microenvironment.
  • Tumor hypoxia influences drug efficacy and toxicity.

Purpose of the Study:

  • To review the mechanisms of bioreductive antitumor agents.
  • To highlight the importance of tumor hypoxia in drug development.
  • To discuss novel quinone, nitro, and N-oxide bioreductive agents.

Main Methods:

  • Literature review of bioreductive antitumor agent mechanisms.
  • Analysis of enzyme activation and bioprotection pathways.
  • Focus on quinone, nitro, and N-oxide compound classes.

Related Experiment Videos

Main Results:

  • Understanding hypoxia is crucial for agent design.
  • Enzyme activity dictates drug efficacy and selectivity.
  • Novel bioreductive agents show promise in preclinical studies.

Conclusions:

  • Rational design of bioreductive agents requires deep mechanistic insight.
  • Targeting tumor hypoxia and specific enzymes enhances therapeutic potential.
  • Further research into quinone, nitro, and N-oxide compounds is warranted.